Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.82 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anastrozole SCHEMBL177942 | 0.91 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL9726 | 0.91 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 0.91 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.89 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL10324455 | 0.87 | CYP19A1 (0.92) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL13323739 | 0.86 | CYP19A1 (0.90) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12908863 | 0.86 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL937176 | 0.85 | CYP19A1 (0.82) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1753732-B1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | CYP19A1 1/4885UGT1A4 1097/4885PDE4D 3162/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885UGT1A4 2132/4885PDE4D 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.